APA

Del Campo J. M., Roszak A., Bidzinski M., Ciuleanu T. E., Hogberg T., Wojtukiewicz M. Z., Poveda A., Boman K., Westermann A. M. & Lebedinsky C. (20100108). Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Del Campo J M, Roszak A, Bidzinski M, Ciuleanu T E, Hogberg T, Wojtukiewicz M Z, Poveda A, Boman K, Westermann A M and Lebedinsky C. 20100108. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Del Campo J. M., Roszak A., Bidzinski M., Ciuleanu T. E., Hogberg T., Wojtukiewicz M. Z., Poveda A., Boman K., Westermann A. M. and Lebedinsky C. (20100108). Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Del Campo J M, Roszak A, Bidzinski M, Ciuleanu T E, Hogberg T, Wojtukiewicz M Z, Poveda A, Boman K, Westermann A M and Lebedinsky C. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. : Annals of oncology : official journal of the European Society for Medical Oncology. 20100108.